ALUMIS INC.

Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company's mission centers on replacing broad immunosuppression with precision-targeted treatments informed by genetic insights and proprietary data analytics.

Alumis was incorporated in January 2021 as FL2021-001, Inc., rebranded as Esker Therapeutics in March 2021, and adopted its current name in January 2022. The company was incubated by Foresite Labs and operates its precision data analytics platform to identify drug targets validated by human genetic evidence and clinical data.

The company's primary focus is its TYK2 inhibitor franchise, anchored by envudeucitinib (envu), a second-generation allosteric TYK2 inhibitor currently in Phase 3 development for moderate-to-severe plaque psoriasis and Phase 2b development for systemic lupus erythematosus. Envu completed enrollment in pivotal Phase 3 ONWARD1 and ONWARD2 trials, with positive topline results reported in early 2026. The company plans to submit a New Drug Application to the FDA in the second half of 2026. Alumis' second TYK2 candidate, A-005, is a CNS-penetrant allosteric TYK2 inhibitor designed for neuroinflammatory and neurodegenerative diseases including multiple sclerosis.

In May 2025, Alumis completed its merger with ACELYRIN, Inc., acquiring lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease treatment. The company is also advancing earlier-stage discovery programs targeting additional immune dysfunction pathways, including interferon regulatory factor 5.

Alumis operates without manufacturing facilities, relying on third-party contract manufacturers for active pharmaceutical ingredients and drug product manufacturing. The company maintains a services agreement with Foresite Labs for data analytics support through December 2026. As a smaller reporting company and emerging growth company, Alumis continues building its pipeline of molecules addressing various immune-mediated diseases through both monotherapy and combination therapy approaches. The company's intellectual property portfolio includes multiple patent families covering composition of matter, methods of use, and formulations for its lead candidates, with protection extending through 2039 to 2046 depending on the specific patent family.